SARS-CoV-2 Neutralization and Serology Testing of COVID-19 Convalescent Plasma from Donors with Nonsevere Disease

Overview

Journal Transfusion

Specialty Hematology

Date 2020 Sep 16

PMID 32935872

Citations 22

Authors

Thomas J Gniadek

Joshua M Thiede

William E Matchett

Abigail R Gress

Kathryn A Pape

Jessica K Fiege

Marc K Jenkins

Vineet D Menachery

Ryan A Langlois

Tyler D Bold

Affiliations

Soon will be listed here.

Abstract

Background: The transfer of passive immunity with convalescent plasma is a promising strategy for treatment and prevention of COVID-19, but donors with a history of nonsevere disease are serologically heterogenous. The relationship between SARS-Cov-2 antigen-binding activity and neutralization activity in this population of donors has not been defined.

Study Design And Methods: Convalescent plasma units from 47 individuals with a history of nonsevere COVID-19 were assessed for antigen-binding activity of using three clinical diagnostic serology assays (Beckman, DiaSorin, and Roche) with different SARS-CoV-2 targets. These results were compared with functional neutralization activity using a fluorescent reporter strain of SARS-CoV-2 in a microwell assay.

Results: Positive correlations of varying strength (Spearman r = 0.37-0.52) between antigen binding and viral neutralization were identified. Donors age 48 to 75 years had the highest neutralization activity. Units in the highest tertile of binding activity for each assay were enriched (75%-82%) for those with the highest levels of neutralization.

Conclusion: The strength of the relationship between antigen-binding activity and neutralization varies depending on the clinical assay used. Units in the highest tertile of binding activity for each assay are predominantly comprised of those with the greatest neutralization activity.

Citing Articles

The Role of Biological Sex in Pre-Clinical (Mouse) mRNA Vaccine Studies.

Binici B, Rattray Z, Schroeder A, Perrie Y Vaccines (Basel). 2024; 12(3).

PMID: 38543916 PMC: 10975141. DOI: 10.3390/vaccines12030282.

Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies.

Jazbec K, Jez M, Ziberna K, Mali P, Ramsak Z, Potokar U Virol J. 2023; 20(1):53.

PMID: 36973781 PMC: 10042109. DOI: 10.1186/s12985-023-02007-0.

The Antibody Response to the BNT162b2 mRNA COVID-19 Booster in Healthcare Workers: Association between the IgG Antibody Titers and Anthropometric and Body Composition Parameters.

Golec M, Konka A, Fronczek M, Zembala-John J, Chrapiec M, Wystyrk K Vaccines (Basel). 2022; 10(10).

PMID: 36298503 PMC: 9611156. DOI: 10.3390/vaccines10101638.

Boosting corrects a memory B cell defect in SARS-CoV-2 mRNA-vaccinated patients with inflammatory bowel disease.

Pape K, Dileepan T, Matchett W, Ellwood C, Stresemann S, Kabage A JCI Insight. 2022; 7(12).

PMID: 35730567 PMC: 9309052. DOI: 10.1172/jci.insight.159618.

Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.

Van Ert H, Bohan D, Rogers K, Fili M, Rojas Chavez R, Qing E Microbiol Spectr. 2022; 10(1):e0267621.

PMID: 35080430 PMC: 8791189. DOI: 10.1128/spectrum.02676-21.

References

Coish J, MacNeil A . Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19. Microbes Infect. 2020; 22(9):405-406. PMC: 7311339. DOI: 10.1016/j.micinf.2020.06.006. View

Long Q, Liu B, Deng H, Wu G, Deng K, Chen Y . Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020; 26(6):845-848. DOI: 10.1038/s41591-020-0897-1. View

Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar G . SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol. 2020; 57(1):e100. PMC: 7235504. DOI: 10.1002/cpmc.100. View

Muruato A, Fontes-Garfias C, Ren P, Garcia-Blanco M, Menachery V, Xie X . A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun. 2020; 11(1):4059. PMC: 7426916. DOI: 10.1038/s41467-020-17892-0. View

Xie X, Muruato A, Lokugamage K, Narayanan K, Zhang X, Zou J . An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe. 2020; 27(5):841-848.e3. PMC: 7153529. DOI: 10.1016/j.chom.2020.04.004. View

Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J . Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients. Clin Infect Dis. 2020; 71(10):2688-2694. PMC: 7314147. DOI: 10.1093/cid/ciaa721. View

Crawford K, Eguia R, Dingens A, Loes A, Malone K, Wolf C . Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses. 2020; 12(5). PMC: 7291041. DOI: 10.3390/v12050513. View

Tenforde M, Rose E, Lindsell C, Shapiro N, Files D, Gibbs K . Characteristics of Adult Outpatients and Inpatients with COVID-19 - 11 Academic Medical Centers, United States, March-May 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(26):841-846. PMC: 7332092. DOI: 10.15585/mmwr.mm6926e3. View

Bloch E, Shoham S, Casadevall A, Sachais B, Shaz B, Winters J . Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020; 130(6):2757-2765. PMC: 7259988. DOI: 10.1172/JCI138745. View

10.

Wolfel R, Corman V, Guggemos W, Seilmaier M, Zange S, Muller M . Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581(7809):465-469. DOI: 10.1038/s41586-020-2196-x. View

11.

Du P, Brendle S, Milici J, Camacho F, Zurlo J, Christensen N . Comparisons of VLP-Based ELISA, Neutralization Assays with Native HPV, and Neutralization Assays with PsV in Detecting HPV Antibody Responses in HIV-Infected Women. J AIDS Clin Res. 2015; 6(3). PMC: 4467835. DOI: 10.4172/2155-6113.1000433. View

12.

Tan C, Chia W, Qin X, Liu P, Chen M, Tiu C . A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020; 38(9):1073-1078. DOI: 10.1038/s41587-020-0631-z. View

13.

Salazar E, Kuchipudi S, Christensen P, Eagar T, Yi X, Zhao P . Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. J Clin Invest. 2020; 130(12):6728-6738. PMC: 7685744. DOI: 10.1172/JCI141206. View

14.

Krammer F, Simon V . Serology assays to manage COVID-19. Science. 2020; 368(6495):1060-1061. DOI: 10.1126/science.abc1227. View

15.

Thomas S, Altawallbeh G, Zaun C, Pape K, Peters J, Titcombe P . Initial determination of COVID-19 seroprevalence among outpatients and healthcare workers in Minnesota using a novel SARS-CoV-2 total antibody ELISA. Clin Biochem. 2021; 90:15-22. PMC: 7849522. DOI: 10.1016/j.clinbiochem.2021.01.010. View